ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • psoriatic arthritis and socio-economic inequities
  • psoriatic arthritis and socioeconomic status
  • psoriatic arthritis and spine involvement
  • Psoriatic arthritis and spondylarthritis
  • psoriatic arthritis and spondylarthropathy
  • psoriatic arthritis and statins
  • psoriatic arthritis and statistical methods
  • psoriatic arthritis and surgery
  • psoriatic arthritis and synovial cells
  • psoriatic arthritis and synovitis
  • psoriatic arthritis and systemic lupus erythematosus (SLE)
  • psoriatic arthritis and therapeutic targeting
  • psoriatic arthritis and therapy
  • psoriatic arthritis and tobacco use
  • psoriatic arthritis and tofacitinib
  • psoriatic arthritis and total joint replacement
  • psoriatic arthritis and treatment
  • psoriatic arthritis and treatment guidlelines
  • psoriatic arthritis and treatment options
  • psoriatic arthritis and tumor necrosis factor (TNF)
  • psoriatic arthritis and ultrasonography
  • Psoriatic arthritis and ultrasound
  • psoriatic arthritis and uveitis
  • Psoriatic arthritis and vaccines
  • psoriatic arthritis and vitamins
  • psoriatic arthritis and weight loss
  • psoriatic arthritis and work
  • psoriatic arthritis and x-ray
  • Psoriatic Arthritis Impact of Disease (PsAID)
  • Psoriatic disease
  • psoriatic nail dystrophy and outcome measures
  • pss
  • psychological status
  • Psychological status and psychological well-being
  • psychological status and quality of life
  • psychological status and rheumatoid arthritis (RA)
  • psychological status and risk
  • psychological status and sleep disorders
  • Psychological status and spondylarthritis
  • psychological status and spondylarthropathy
  • Psychological status and vasculitis
  • psychological well-being
  • psychological well-being and psychosocial factors
  • psychological well-being and rheumatoid arthritis (RA)
  • psychological well-being and spondylarthritis
  • psychological well-being and systemic sclerosis
  • psychology and socioeconomic status
  • Psychometrics
  • psychosocial
  • psychosocial and psychological well-being
  • psychosocial and quality improvement
  • psychosocial and stress
  • psychosocial and systemic lupus erythematosus (SLE)
  • psychosocial and systemic sclerosis
  • Psychosocial and vasculitis
  • psychosocial factors
  • psychosocial factors and quality of life
  • psychosocial factors and rehabilitation
  • psychosocial factors and rheumatoid arthritis (RA)
  • Psychosocial factors and scleroderma-like conditions
  • psychosocial factors and stress
  • Psychosocial factors and systemic sclerosis
  • psychosocial factors and total joint replacement
  • psychosocial factors and vasculitis
  • Psychosocial support and Support and education
  • Puberty
  • Puberty and juvenile idiopathic arthritis (JIA)
  • Public Health Approach
  • Public Health Approach and juvenile arthritis
  • Public Health Approach and musculoskeletal disorders
  • Public Health Approach and recruiting
  • Publication
  • pulmonary
  • Pulmonary arterial hypertension
  • pulmonary arterial hypertension and risk assessment
  • pulmonary complications
  • pulmonary complications and computed tomography (CT)
  • pulmonary complications and cytokines
  • pulmonary complications and heart disease
  • pulmonary complications and Idiopathis Inflammatory Myopathies (IIM)
  • pulmonary complications and radiology
  • pulmonary complications and regulatory cells
  • pulmonary complications and rheumatoid arthritis (RA)
  • pulmonary complications and risk
  • pulmonary complications and risk assessment
  • Pulmonary complications and scleroderma
  • pulmonary complications and systemic lupus erythematosus (SLE)
  • pulmonary complications and systemic sclerosis
  • Pulmonary complications and systemic vasculitides
  • pulmonary complications and treatment
  • pulmonary complications and vasculitis
  • pulmonary fibrosis
  • pulmonary fibrosis and interstitial lung disease
  • pulmonary fibrosis and prognostic factors
  • pulmonary fibrosis and rheumatoid arthritis
  • pulmonary fibrosis and rheumatoid arthritis (RA)
  • pulmonary fibrosis and scleroderma
  • pulmonary fibrosis and serologic tests
  • pulmonary fibrosis and systemic sclerosis
  • pulmonary fibrosis and transforming growth factor
  • pulmonary fibrosis and vasculitis
  • Pulmonary hypertension
  • Pulmonary Involvement
  • Pulmonary Involvement and anti-TNF therapy
  • Pulmonary Involvement and antibodies
  • Pulmonary Involvement and autoantibodies
  • Pulmonary Involvement and connective tissue diseases
  • Pulmonary Involvement and mixed connective tissue disease (MCTD)
  • Pulmonary Involvement and polymyositis/dermatomyositis (PM/DM)
  • Pulmonary Involvement and radiology
  • Pulmonary Involvement and rheumatoid arthritis (RA)
  • Pulmonary Involvement and scleroderma
  • Pulmonary Involvement and Sjogren's syndrome
  • Pulmonary Involvement and surgery
  • Pulmonary Involvement and systemic sclerosis
  • Pulmonary Involvement and vasculitis
  • Pulmonary Involvement and Wegener's granulomatosis
  • pulmonary sarcoidosis
  • pulse steroids
  • Pyruvate dehydrogenase kinase
  • QT Interval
  • QTc inteval
  • qualitative
  • qualitative and quality improvement
  • qualitative and quality of care
  • qualitative and quality of life
  • qualitative and race/ethnicity
  • qualitative and remission
  • qualitative and rheumatoid arthritis (RA)
  • qualitative and self-management
  • qualitative and shared dicision making
  • qualitative and spondylarthritis
  • qualitative and Support and Education Groups
  • qualitative and systemic lupus erythematosus (SLE)
  • qualitative and systemic sclerosis
  • qualitative and technology
  • qualitative and well-being
  • qualitative and work
  • qualitative and young adults
  • Qualitative Research
  • Quality
  • quality and quality improvement
  • quality and race/ethnicity
  • quality and registry
  • quality and rheumatoid arthritis (RA)
  • Quality and vaccines
  • quality improvement
  • quality improvement and access to care
  • quality improvement and pediatric rheumatology
  • quality improvement and phone
  • quality improvement and polymyositis/dermatomyositis (PM/DM)
  • quality improvement and quality measures
  • quality improvement and quality of care
  • quality improvement and rheumatic disease
  • Quality improvement and rheumatoid arthritis
  • quality improvement and rheumatoid arthritis (RA)
  • Quality improvement and rheumatologic disease
  • quality improvement and ribonucleoprotein (RNP)
  • quality improvement and safety
  • quality improvement and self-management
  • quality improvement and serologic tests
  • quality improvement and shared dicision making
  • quality improvement and spondylarthritis
  • quality improvement and steroids
  • quality improvement and systemic lupus erythematosus (SLE)
  • quality improvement and technology
  • quality improvement and tobacco use
  • quality improvement and trainee
  • quality improvement and tuberculosis
  • quality improvement and urate
  • quality improvement and uric acid
  • quality improvement and uveitis
  • Quality improvement and vaccines
  • quality improvement and women's health
  • Quality Indicators
  • Quality Indicators and benchmarking tools
  • Quality Indicators and osteoporosis
  • Quality Indicators and quality measures
  • Quality Indicators and quality of care
  • Quality Indicators and rheumatoid arthritis (RA)
  • Quality Indicators and SLE
  • quality measures
  • quality measures and doctor-patient relationship
  • quality measures and quality of care
  • quality measures and quality reporting
  • quality measures and qulaity of care
  • quality measures and rheumatic disease
  • Quality measures and rheumatoid arthritis (RA)
  • quality measures and subchondral bone
  • quality measures and systemic sclerosis
  • quality measures and technology
  • quality measures and therapeutic targeting
  • quality of care
  • quality of care and quality of life
  • Quality of care and questionnaires
  • quality of care and randomized trials
  • quality of care and registries
  • quality of care and registry
  • Quality of care and rheumatoid arthritis
  • quality of care and rheumatoid arthritis (RA)
  • First |
  • « Previous Page
  • 48
  • 49
  • 50
  • 51
  • 52
  • [53]
  • 54
  • 55
  • 56
  • 57
  • 58
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology